213 related articles for article (PubMed ID: 20544193)
21. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
DeGrado TR; Baldwin SW; Wang S; Orr MD; Liao RP; Friedman HS; Reiman R; Price DT; Coleman RE
J Nucl Med; 2001 Dec; 42(12):1805-14. PubMed ID: 11752077
[TBL] [Abstract][Full Text] [Related]
24. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129
[TBL] [Abstract][Full Text] [Related]
25. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.
Beauregard JM; Williams SG; Degrado TR; Roselt P; Hicks RJ
J Med Imaging Radiat Oncol; 2010 Aug; 54(4):325-32. PubMed ID: 20718912
[TBL] [Abstract][Full Text] [Related]
26. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
[TBL] [Abstract][Full Text] [Related]
27.
Grkovski M; Kohutek ZA; Schöder H; Brennan CW; Tabar VS; Gutin PH; Zhang Z; Young RJ; Beattie BJ; Zanzonico PB; Huse JT; Rosenblum MK; Blasberg RG; Humm JL; Beal K
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1446-1457. PubMed ID: 31865407
[TBL] [Abstract][Full Text] [Related]
28. [Focus: Prostate cancer and PET-choline].
Brenot-Rossi I
Prog Urol; 2014 Jan; 24(1):3-8. PubMed ID: 24365622
[TBL] [Abstract][Full Text] [Related]
29. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.
Kwee SA; Wei H; Sesterhenn I; Yun D; Coel MN
J Nucl Med; 2006 Feb; 47(2):262-9. PubMed ID: 16455632
[TBL] [Abstract][Full Text] [Related]
30.
Metser U; Berlin A; Halankar J; Murphy G; Jhaveri KS; Ghai S; Tau N
AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
[TBL] [Abstract][Full Text] [Related]
31. Role of PET-CT with
Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
[TBL] [Abstract][Full Text] [Related]
32. Comparison of
Gauthé M; Zarca K; Aveline C; Lecouvet F; Balogova S; Cussenot O; Talbot JN; Durand-Zaleski I
BMC Med Imaging; 2020 Mar; 20(1):25. PubMed ID: 32122345
[TBL] [Abstract][Full Text] [Related]
33. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
[TBL] [Abstract][Full Text] [Related]
34.
Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
[TBL] [Abstract][Full Text] [Related]
35. "Real-world" evaluation of
Niziers V; Boissier R; Borchiellini D; Deville JL; Khoury C; Durand M; Toledano H; Albert T; Branger N; Bandelier Q; Ouvrier MJ; Gabriel S; Hoch B; Gross E; Walz J; Brenot-Rossi I; Pignot G
Urol Oncol; 2020 Jan; 38(1):2.e1-2.e9. PubMed ID: 31447087
[TBL] [Abstract][Full Text] [Related]
36. Transcriptomics Associates Molecular Features with
Kwee SA; Tiirikainen M; Sato MM; Acoba JD; Wei R; Jia W; Le Marchand L; Wong LL
Cancer Res; 2019 Apr; 79(7):1696-1704. PubMed ID: 30760520
[TBL] [Abstract][Full Text] [Related]
37. Choline PET/CT for imaging prostate cancer: an update.
Kitajima K; Murphy RC; Nathan MA
Ann Nucl Med; 2013 Aug; 27(7):581-91. PubMed ID: 23632880
[TBL] [Abstract][Full Text] [Related]
38. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
[TBL] [Abstract][Full Text] [Related]
40. Imaging of Prostate Cancer Using
Hodolič M
PET Clin; 2017 Apr; 12(2):173-184. PubMed ID: 28267451
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
